Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28542250 | 1.00 | RET (0.45) | RETSYKOPRK1CKS1BSKP1 | |
| SCHEMBL28542249 | 1.00 | RET (0.45) | RETSYKOPRK1CKS1BSKP1 | |
| SCHEMBL21564571 | 1.00 | RET (0.45) | RETSYKOPRK1CKS1BSKP1 | |
| SCHEMBL21564574 | 1.00 | RET (0.45) | RETSYKOPRK1CKS1BSKP1 | |
| SCHEMBL28709581 | 0.89 | RET (0.55) | RETSYKOPRK1CKS1BSKP1 | |
| SCHEMBL389068 | 0.85 | SYK (0.53) | RETSYKCKS1BSKP1SKP2 | |
| SCHEMBL390147 | 0.85 | SYK (0.53) | RETSYKCKS1BSKP1SKP2 | |
| SCHEMBL389069 | 0.85 | SYK (0.53) | RETSYKCKS1BSKP1SKP2 | |
| SCHEMBL21551489 | 0.85 | OPRK1 (0.45) | SYKOPRK1JAK3CHRM4 | |
| SCHEMBL21551488 | 0.85 | OPRK1 (0.45) | SYKOPRK1JAK3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | RET 1057/4885SYK 4832/4885OPRK1 4795/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | RET 1057/4885SYK 4832/4885OPRK1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.